BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
Stock Information for BioXcel Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.